Cost effectiveness of lowering cholesterol. Study greatly underestimates the cost effectiveness of statin treatment.
作者信息
McMurray J J, Morrison C E
出版信息
BMJ. 1996 Nov 2;313(7065):1142; author reply 1144. doi: 10.1136/bmj.313.7065.1142a.
Abstract
摘要
相似文献
1
Cost effectiveness of lowering cholesterol. Study greatly underestimates the cost effectiveness of statin treatment.降低胆固醇的成本效益。该研究极大地低估了他汀类药物治疗的成本效益。
BMJ. 1996 Nov 2;313(7065):1142; author reply 1144. doi: 10.1136/bmj.313.7065.1142a.
2
Cost effectiveness of lowering cholesterol. Statin treatment should be started early.降低胆固醇的成本效益。他汀类药物治疗应尽早开始。
BMJ. 1996 Nov 2;313(7065):1143; author reply 1144. doi: 10.1136/bmj.313.7065.1143a.
3
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.西班牙降胆固醇疗法的成本效益分析。
Am J Cardiovasc Drugs. 2006;6(3):177-88. doi: 10.2165/00129784-200606030-00005.
4
Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.哪种他汀类药物治疗高胆固醇血症最有效？一项成本效益分析。
Clin Ther. 1999 Nov;21(11):1924-36. doi: 10.1016/S0149-2918(00)86740-5.
5
[Limitations of interventions against hypercholesterolemia].
Aten Primaria. 1996 Mar 15;17(4):305-6.
6
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.辛伐他汀治疗降低冠心病患者胆固醇水平的成本效益。斯堪的纳维亚辛伐他汀生存研究组。
N Engl J Med. 1997 Jan 30;336(5):332-6. doi: 10.1056/NEJM199701303360503.
7
[Lowering LDL cholesterol with Simvastatin. Also, economically reasonable!].使用辛伐他汀降低低密度脂蛋白胆固醇。此外，经济上也合理！
Internist (Berl). 1995 Aug;36(8 Suppl):1-4.
8
[Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].[使用辛伐他汀和考来烯胺降低血液胆固醇的成本效益]
Ned Tijdschr Geneeskd. 1991 Apr 13;135(15):655-9.
9
Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.辛伐他汀与考来烯胺的成本效益：瑞典的研究结果
Pharmacoeconomics. 1992 Mar;1(3):213-6. doi: 10.2165/00019053-199201030-00009.
10
[Data on cholesterol level screening of patients with ischemic heart disease in the light of the Scandinavian Simvastatin Survival Study].
Orv Hetil. 1997 Jun 29;138(26):1679-82.
引用本文的文献
1
[Are the Framingham tables directly applicable to the Mediterranean population?].[弗雷明汉表格是否直接适用于地中海人群？]
Aten Primaria. 2002 Jun 15;30(1):29-31. doi: 10.1016/s0212-6567(02)78960-9.
本文引用的文献
1
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.他汀类药物降低已有或无冠心病患者胆固醇浓度的成本效益：应用于卫生当局人群的生命表法
BMJ. 1996 Jun 8;312(7044):1443-8. doi: 10.1136/bmj.312.7044.1443.
2
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.
Circulation. 1996 May 15;93(10):1796-802. doi: 10.1161/01.cir.93.10.1796.
3
Cholesterol lowering and mortality: the importance of considering initial level of risk.降低胆固醇与死亡率：考虑初始风险水平的重要性。
BMJ. 1993 May 22;306(6889):1367-73. doi: 10.1136/bmj.306.6889.1367.
4
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.普伐他汀预防高胆固醇血症男性冠心病。苏格兰西部冠心病预防研究组。
N Engl J Med. 1995 Nov 16;333(20):1301-7. doi: 10.1056/NEJM199511163332001.
5
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease.用于冠心病一级预防的胆固醇降低的谢菲尔德风险与治疗表。
Lancet. 1995 Dec 2;346(8988):1467-71. doi: 10.1016/s0140-6736(95)92477-9.
Zotero 插件